1. Home
  2. TENB vs LQDA Comparison

TENB vs LQDA Comparison

Compare TENB & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tenable Holdings Inc.

TENB

Tenable Holdings Inc.

HOLD

Current Price

$17.78

Market Cap

2.7B

Sector

Technology

ML Signal

HOLD

LQDA

Liquidia Corporation

HOLD

Current Price

$31.92

Market Cap

3.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TENB
LQDA
Founded
2002
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.7B
3.1B
IPO Year
2018
2020

Fundamental Metrics

Financial Performance
Metric
TENB
LQDA
Price
$17.78
$31.92
Analyst Decision
Buy
Strong Buy
Analyst Count
20
10
Target Price
$35.53
$38.60
AVG Volume (30 Days)
3.1M
1.7M
Earning Date
05-05-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
54.41
N/A
EPS
N/A
N/A
Revenue
$900,021,000.00
$13,996,000.00
Revenue This Year
$9.37
$993.31
Revenue Next Year
$7.04
$219.14
P/E Ratio
N/A
N/A
Revenue Growth
12.68
N/A
52 Week Low
$19.15
$11.26
52 Week High
$39.13
$46.67

Technical Indicators

Market Signals
Indicator
TENB
LQDA
Relative Strength Index (RSI) 27.10 32.94
Support Level N/A $29.30
Resistance Level $23.33 $36.07
Average True Range (ATR) 1.40 2.76
MACD -0.20 -1.36
Stochastic Oscillator 0.80 3.73

Price Performance

Historical Comparison
TENB
LQDA

About TENB Tenable Holdings Inc.

Founded in 2002, Tenable is a cybersecurity company that began providing vulnerability management solutions under its Nessus software. In recent years, Tenable has expanded its portfolio to provide a broader range of exposure management modules. Solutions include cloud security and compliance, active directory management, operational technology security and advanced vulnerability analytics. The Maryland-based company went public in 2018.

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

Share on Social Networks: